Tag Archives: stem cells

Ocata publishes Phase 2 trial protocol!!

Here it is!! On clinicaltrials.gov!! YES and YAY. We are getting closer and closer to a cure for the most common cause of blindness in the developed world. There’s only one possible response to this… make a pumpkin pie! 🙂 (Oh, okay, I was already going to do that anyway…) But I’ll let you know how it turned out. For a truly excellent article explaining what this means, I’ll send you to the one and only Dr. Hartman’s (aka Deadally’s) analysis on Seeking Alpha:
Ocata Therapeutics Is An Official Phase 2 Biotech: AMD Efficacy Study Design Details

And here’s a comment I just left on the article:

Thanks so much for this excellent article, Dr. Hartman! 🙂 So many people could be helped this way. And as I know all too well… NOT everyone who has some form of MD is ninety years old. I’m certainly not, but it does get worse than that. Every time I’ve been at Casey Eye Institute, I’ve seen small children with Stargardt’s. It’s one of the saddest sights you could ever imagine. I know I’ll never forget the time I saw a baby with bandages over its face being wheeled down the hall in a huge cot enclosed by bars. What Ocata is doing will ultimately provide the opportunity to save people of all ages from blindness.

First Patient Enrolled in Ocata Therapeutics’ Phase 2 Study for Dry AMD Results from First Cohort Expected in the Second Quarter of 2016

Here’s the press release.
(STARES at today’s news)

*^()&)*(&)*(&)*( I DON’T EVEN.
(RUNS around yelling incoherently, but happily.)

INFINITE YAY.
THIS… this is what we’ve been waiting for. Ocata is officially now going to start Phase 2 of the AMD study.

There’s so much to be said here… it’ll have to get done later on… but for now… HAPPY. Just plain… happy. 🙂

News From Europe!:)

Check this out!!

The EU agrees to fast track desperately needed meds.

The EU is pulling FAR ahead of us with this one. The European Medicines Agency (EMA) has decided that trial medications for incurable and untreatable diseases can be fast tracked and approved for use with small populations– IF they’re getting great results. (Such as the success that Ocata has shown with its stem cell based cure for the most common cause of blindness in the developed world. HINT HINT HINT.) That is not happening here.There is no genuine fast track for medications that show that kind of desperately needed promise. The “breakthrough status” that is available for these types of meds is very inadequate.Very few medications have ever been granted this status until Phase III of testing; real promise might be shown much earlier than that. And quite honestly, this situation why I decided to support the Right to Try laws in the U.S. As imperfect as they are (and they do have issues, beyond a doubt) they may provide pressure for the FDA to adopt the same thing that the EMA has now done.

It’s easy to say that adopting the same policies in the U.S. would lead to little regulation, and that is a real concern. But look at what’s happening here. The EU is not somehow throwing out all regulation.In fact, that’s just what they’re avoiding with this decision. Here’s why. If you or a loved one ever have a terminal/disabling disease, reason and logic will go straight to hell. You won’t care what’s regulated or what isn’t. Believe me, you won’t. You’ll do anything at all that might help– and that means you’ll be vulnerable to some really bad choices. People do make those questionable choices right now, and there are more of them available than ever before (illegal stem cell clinics being a good example.) The only way to stop this is to give desperate people other options.

The EU is doing what they need to do in order to accomplish this. We can do it too, and we have to. We can’t play these games with people’s lives anymore here while the rest of the world figures out exactly how to help those who suffer.

Amazing news from Ocata!!

This is REALLY exciting… I had a few thoughts about it to share on Facebook, and I’m reposting them here:

Cures for autoimmune diseases ARE possible!! They’re on their way, and they could be almost here! Well, there’s just ONE problem… they originally came from a stem cell line where at SOME point, LONG long ago, a three day old blastocyst was destroyed. One that would otherwise have been thrown out at a fertility clinic. One that never had a chance of being an embryo. Fifty million people have autoimmune diseases in America alone. Are they more important than one blastocyst that was sacrificed years ago? There are people who say yes. We are headed for a showdown. Share if you are on the side of the fifty million!!

New Ocata Press Release About Autoimmune Treatments in the Pipeline!!

Right to Try Bill in Oregon: What’s Going On?

Hey all, so here’s the archived public hearing in the Oregon Senate on Right to Try, HB 2300! Check it out.
Link to the public hearing on June 1st.

So what’s going on right now? With just a little more digging, I found out. HB 2300 is in a senate committee, and there will be another hearing on Wednesday, June 3rd, at 3:00. Let’s keep our fingers crossed!

Here’s where you can go to track the progress of the Oregon bill.

Florida Council of Bishops Attacks Right to Try Law– What Will This Mean?

Okay, so let’s put this issue in context. I am not an atheist.(Although my sister is– hi, Chris!) But the actions of religious groups related to Right to Try laws are becoming really disturbing, and quite honestly, hypocritical as could be. Hypocrisy has got to be my least favorite quality, and the Florida Council of Bishops is putting on a big display of that quality right now.

On one hand, they’re demanding that “good Catholic business people who can’t in good conscience cooperate with this” shouldn’t have to provide contraception coverage for employees under federal law. (See? Right here. Catholic Bishops Demand All Businesses Be Given The Right To Deny Women Contraception Coverage

BUT all that concern about individual rights was trashed when it came to Florida’s Right to Try law last month.Basically, here’s what happened:

The Florida Conference of Catholic Bishops and Florida Right to Life now oppose the Senate version of the “Right to Try Act” (SB 1052) because Sen. Jeff Brandes, R-St. Petersburg, the bill sponsor, has added a provision dealing with end-of-life decisions by the patients.

The groups are specifically questioning an amendment that would let Florida join more than two dozen states that allow frail or terminally ill patients to arrange for a “physician order for life-sustaining treatment” (POLST), which outlines specific end-of-life procedures. For instance, the POLST — which is an arrangement between the patient and his or her physician — could determine whether the patient would receive tube feedings or would opt for medical care for “comfort only” rather than more intensive treatments.

So what does this really mean? They’re willing to keep terminal patients from the right to try experimental drugs so that they can keep people from the right to end their own lives. Whatever happened to ALL that concern about civil liberties they had for business owners???

See what I mean about the hypocrisy?
Continue reading

Right to Try: My Latest Thoughts

So Paul Knoepfler has an excellent article on his take on Right to Try on his blog (find it right here.) I think that it’s balanced in a lot of ways, and yet I do have to say that I think there are more issues that need to be take into account. There’s a piece of advice that I’ve seen floating around the web for quite a while: if you write something online that you feel is significant, make sure that it’s preserved in a more permanent way than on Facebook, as a comment on someone else’s post, etc etc etc. That’s what I’ve done here. 🙂 So… here’s my comment on Paul Knoepfler’s post on Right to Try issues.
Continue reading

More Details About That South Korean Study

Here’s the link for the original South Korean article showing even more positive results for patients when the Ocata technique was used. This is a much smaller study with only four people, and I think the real value is that it supports the original results in the Lancet. There were two AMD and two SMD patients, and when I read the full article, I could see that all of them had improvements. Three were very significant (vision improved 50%, 100% (twice as good, and I can never remember if that should be 100% or 200%), and 1300% improvement– yes, vision that was thirteen times better than before the study!

The fourth person wasn’t considered to have significant improvement, but I’m not so sure that I would agree. Their vision went from being able to read one letter to two, and when your vision is that bad to start with, any improvement helps.

Anyway… I highly recommend reading the whole article. The complete pdf if available for free, which is usually not the case– so take advantage of it!

Treatment of Macular Degeneration Using Embryonic Stem Cell-Derived Retinal Pigment Epithelium: Preliminary Results in Asian Patients

New Ocata Press Release!

YES! These are the results we’ve been waiting for from CHA in So. Korea. They are great, and they 100% support the Lancet results from Ocata’s own trials. The thing that really impresses me about the CHA results is that just like Ocata’s, they were published in a peer-reviewed journal instead of being released through a company announcement. I have to say, I’m kind of over company announcements. (Remember when StemCells Inc did that??) Anyone can announce anything. I can announce that I just won Powerball. That doesn’t make it true! An article in a peer-reviewed journal is the gold standard.

Anyway, here’s a snippet, although you really need to go the link:
Continue reading

The UC-Davis Stem Cell Ethics Conference, Part Eight: A Profile in Courage

Here it is, and you don’t want to miss this one! The ending just might be my favorite bit so far.

In the brief break between speakers, I quickly looked over my notes about ALS. 8 out of 100,000 people were affected. There were many different phenotypes, some sporadic; some genetic; some caused by God only knew what. Even when ALS was familial, the specific genes involved were very difficult to pin down. Abnormal ones could occasionally be successfully targeted with success, but that was rare. There had been 160 treatment trials in the past 5 years, and out of those, only one effective drug had emerged, which was Riluzole.. And “effective” was a relative word in that case, to say the least.
Continue reading